New pill tested to calm overactive immune system in lupus

NCT ID NCT02472795

Completed Disease control Sponsor: Viatris Innovation GmbH Source: ClinicalTrials.gov ↗

Summary

This study tested a new oral medication called cenerimod in people with systemic lupus erythematosus (SLE). The main goal was to see if the drug could safely reduce the number of specific immune cells (lymphocytes) in the blood, which are thought to drive the disease. About 105 adults with active lupus took different doses of the drug or a placebo daily for 12 weeks to measure its effects and safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigator Site

Anniston, Alabama, 36207, United States
Investigator Site

Clearwater, Florida, 33765, United States
Investigator Site

Minsk, 220116, Belarus
Investigator Site

Minsk, 223041, Belarus
Investigator Site

Vitebsk, 210037, Belarus
Investigator Site

Plovdiv, 4000, Bulgaria
Investigator Site

Plovdiv, 4002, Bulgaria
Investigator Site

Sofia, 1612, Bulgaria
Investigator Site

Tbilisi, 0186, Georgia
Investigator Site

Kemerovo, 650066, Russia
Investigator Site

Kursk, 305007, Russia
Investigator Site

Omsk, 644111, Russia
Investigator Site

Orenburg, 460018, Russia
Investigator Site

Smolensk, 214025, Russia
Investigator Site

Vladimir, 600023, Russia
Investigator Site

Vinnytsia, 21018, Ukraine
Investigator Site

Vinnytsia, 21029, Ukraine
Investigator Site

Zaporizhia, 69600, Ukraine

Conditions

Explore the condition pages connected to this study.

SYSTEMIC LUPUS ERYTHEMATOSUS